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INTRODUCTION
The Core outcome set for Venous leg ulceration 
(CoreVen) project was established in 2016 and is 
registered on the COMET database (http://www.
comet-initiative.org/studies/details/680). The 
project aims to develop a minimum list of out-
comes on the effectiveness of interventions used in 
venous leg ulceration (VLU) and their associated 
measurement instruments for reporting in clinical 
trials. The principal investigators are Prof. Andrea 
Nelson (University of Leeds, UK) and Dr Geor-
gina Gethin (NUI Galway, Ireland). Sarah Hallas 
is a PhD student on the project, and Mary Burke 
is an MSc Student. Supervision of these students 
is provided by Dr Susan O’Meara (University of 
Leeds), Prof. Andrea Nelson, and Dr Georgina 
Gethin. The steering group represents a range of 
disciplines from multiple European countries: Dr 
Una Adderley (Lecturer and Researcher in Com-
munity Nursing, University of Leeds, UK), Dr Jan 
Kottner (Scientific Director of Clinical Research 
for Hair and Skin Science, Department of Derma-
tology and Allergy, Charite-Universitatsmedizin 
Berlin, Berlin, Germany), Dr Mary Madden (Lec-
turer and Researcher in Applied Health Research, 
University of Leeds, UK), Dr Pauline Meskell 
(Senior lecturer and researcher at the Nursing 
and Health Research Department, University 
of Limerick, Ireland), Prof. Jane Nixon (Deputy 
Director Institute Clinical Trials Research, Uni-
versity of Leeds, UK), Dr Aonghus O’Loughlin 
(Consultant Endocrinologist, Bons Secours Hos-
pital, Galway, Ireland and an Alliance for Research 
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and Innovation in Wounds Steering Committee 
Member), Prof. Sebastian Probst (Professor of 
Tissue Viability and Wound Care, University of 
Applied Sciences Western Switzerland, Geneva, 
Switzerland and Council Member and Editor, 
EWMA), Mr Wael Tawfick (Vascular Surgeon 
Saolta University Health Care Group, University 
Hospital Galway, and the School of Medicine, 
National University of Ireland Galway, Ireland, 
and an Alliance for Research and Innovation in 
Wounds Steering Committee Member), and Dr 
Thomas Wild (General Surgeon, specialising in 
wound management and septic surgery, University 
Medical Center Hamburg-Eppendorf, Germany 
and Editor-in-Chief, Wound Medicine).
AIMS OF THE MEETING
The aim of the meeting was to introduce the pro-
ject, its rationale, its purpose, and progress to date 
as well as to gain feedback on the proposed meth-
odology. The project team members are grateful to 
the EWMA for facilitating this first open meeting.
ATTENDANCE AT THE MEETING
Notification of the meeting was provided in the 
conference programme and on the website and 
was therefore open to all delegates. Key opinion 
leaders in VLU management who were attending 
the conference were informed of the meeting, and 
pre-conference notifications were sent to contacts. 
A total of 52 people attended the meeting from 
various backgrounds, which included patient 
organisation representatives, vascular surgeons, 
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physicians, dermatologists, podiatrists, nurses, sociologists, 
and researchers.
BACKGROUND
A core outcome set (COS) is a minimum set of outcomes 
that should be measured and reported in all clinical trials 
for a specific clinical area as agreed on by stakeholders in 
that field1. An outcome is any identifiable consequence of 
the exposure to a health care intervention, such as a drug 
or a dressing. An outcome must be appropriate, measur-
able, and meaningful to stakeholders. COS are gaining 
recognition as a means of improving the potential for meta-
analysis within systematic reviews and ultimately synthesis-
ing results of trials that include outcomes of importance 
to patients and key stakeholders. A COS also reduces the 
risk of outcome-reporting bias2. For example, in the ab-
sence of these minimum requirements, the presentation 
of findings may be limited to outcomes with statistically 
significant results. The implementation of the COS for 
VLUs by researchers will increase the utility of trials in this 
field and facilitate comparison amongst different sources 
of evidence. Many areas of healthcare have developed a 
COS, such as the Outcome Measures in Rheumatology 
(OMERACT;3), the management of Otitis Media with 
Effusion in children with cleft palate (mOMEnt;4), and 
Harmonizing Outcome Measures for Eczema (HOME;5). 
To date, however, no standardised methods of assessment 
or COS exist for VLU management, and three previous 
systematic reviews have identified the diversity of outcomes 
in RCTs in this field6,7,8. 
A recent qualitative study9 that aimed to identify the most 
important outcomes for complex wounds from the per-
spectives of patients, carers, and healthcare professionals 
found that most patients with VLUs, including intrave-
nous drug users, and healthcare professionals involved in 
their care regarded the healing of the wound as the primary 
treatment goal. Patients were greatly troubled by the so-
cial consequences of having a complex wound. Thus, the 
CoreVen project team is working together to develop a 
minimum list of outcomes for VLU trials.
A VLU is a chronic wound that occurs below the knee and 
takes more than six weeks to heal9. A VLU is a chronic 
and reoccurring condition11 that is caused by impaired 
venous blood flow triggered by venous hypertension. The 
prevalence of VLUs has been estimated at 0.29 per 1000 
individuals in the UK (95% confidence interval 0.25-
0.33)12. Estimates in the Western world suggest that 1% 
of the population experience VLUs, and this rate could be 
as high as 3% in people over the age of 65 years13. Venous 
hypertension results in damage to the valves in the legs, al-
lowing two-way blood flow to occur instead of the normal 
one-way flow of blood and resulting in swelling of the leg 
veins, oedema, and leakage of circulatory fluid into the 
surrounding tissue from the capillaries in the lower legs14. 
VLU can result in pain, malodour, susceptibility to infec-
tion, and lack of mobility15. These issues, in turn, affects 
the patient’s quality of life through reduction in social 
activity, limits on their capacity to work, and inability to 
perform self-care and personal hygiene activities9,16. In 
order to ensure individuals receive good quality care and 
treatment supported by evidence-based practice, effective 
treatments must be developed and rigorously tested.
The lack of consistency in clinical trial outcomes means 
that it is difficult to compare results of clinical trials or 
to perform meta-analysis6. This lack of consistency lim-
its clinical judgments, as trials often have numerous and 
different outcomes. Often the choice of outcomes is not 
carefully considered as many of the outcomes are not re-
garded as important by patients. The use of these outcomes 
in clinical trials has led to waste in study resources and 
reporting, and these issues may be avoidable with the use 
of a COS2. Another challenge is that different trials use 
different measurement instruments at different time points 
and often with little reference to the validity and reliability 
of such instruments6. These issues underscore the need to 
develop COS and appropriate measurement instruments 
for clinical trials for VLU treatment.
While no single method of developing a COS is accepted, 
a multi-stage process in which all stakeholders, including 
patients and their carers, contribute to the final outcome 
set will be the most useful. Firstly, a core domain set is 
established. This step is followed by development of a con-
sensus minimal set of outcomes that should be reported 
for any trial. Finally, consensus on how the outcomes are 
to be measured with respect to validity and reliability of 
the measurement instruments is achieved amongst the 
participating stakeholders.
DEVELOPMENT OF COS
IDENTIFICATION OF POTENTIAL OUTCOMES
Scoping review
The results of a scoping review, which included all out-
comes identified in the Cochrane Systematic Review da-
tabase that included RCTs in patients with VLU, were 
presented at the meeting. A scoping review enabled the 
concepts in a field of interest to be ‘mapped’ out17 and 
allowed for a rapid underpinning of the key concepts18. 
The adaptation of the Arksey and O’Malley17 five-stage 
methodological framework for conducting a scoping re-
view by Levac et al.19 was used to guide the review. Stage 
1 identified the research question, which although broad, 
still includes the study population. In this case, the study 
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population included people with VLUs. Stage 2 identified 
the relevant studies, which were RCTs included in the 
Cochrane systematic reviews. Stage 3 defines the study 
selection. Levac et al19 recommended that the inclusion 
and exclusion criteria can be applied post hoc as the re-
searcher becomes increasingly familiar with the literature. 
The charting of the data (Stage 4) was designed according 
to the framework analysis of Ritchie and Spencer20. In 
this stage, the outcomes were organised into a structured 
table that facilitated the grouping of the outcomes into 
domains. The results were collated, summarised, and re-
ported in Stage 5.
In total, 807 (post-deduplication) potential outcomes were 
extracted. Through consensus amongst the group mem-
bers, these 807 outcomes were grouped into 11 domains 
(Table) and presented at the meeting. Domains are broad, 
descriptive categories that host potential groupings of sev-
eral, more specific, outcomes.
Table: 
Domains identified following the 
scoping review.
n Healing
n Patient-reported symptoms
n Clinician-reported symptoms
n Carer-reported symptoms 
n Life impacts
n Clinical signs
n Clinical measurement
n Performance of the intervention
n Resource use: supplies
n Resource use: clinician time
n Adverse events
CONSENSUS METHODS DISCUSSION
The method to be used to gain consensus from stake-
holders was openly discussed at the EWMA meeting. 
The following topics were introduced, and agreement 
was achieved.
n Stakeholders will include patients, carers, health profes-
sionals, policy makers, researchers, and industry repre-
sentatives. Two members (Nelson and O’Meara) of the 
project team are editors for Cochrane Wounds Group 
(CWG), ensuring the involvement of a broad range of 
stakeholders. Other steering group members also have 
expertise in Cochrane Reviews. We are also likely to 
contact additional people who contribute to the CWG 
(e.g., review authors and editors) through the proposed 
networks.
n The Delphi method will be used via an online survey 
tool (Bristol Online Survey) to gain consensus on the 
domains. Participants will be asked to rate each domain 
in terms of importance on a Likert scale of 1 to 9 (1 
being not important, and 9 being extremely impor-
tant). Discussion with the audience suggested that most 
people were in favour of including two rounds for each 
step of the consensus process. The rationale behind this 
is that it is methodologically defensible. That is, with 
two rounds, we will be able to better identify and un-
derstand the complexities of the decision process, in 
agreement with processes for other COS21.
n An audience member highlighted the fact that an online 
format has methodological limitations and may be 
limited in its ability to reach the patient group. This 
challenge was discussed and acknowledged by the team. 
Because of funding restraints, however, it will not be 
possible to send out paper copies of the survey. Paper 
formats are also much more time consuming. The sur-
vey will benefit from the ‘snowball’ effect, in that the 
number of people that have the opportunity to par-
ticipate will be increased via links from wound care 
organisations and all other known networks with an 
interest in VLU research; however, individuals will not 
be contacted by their National Health Service (NHS) 
UK use or employment. Ethical approval for this step 
has been sought from the University of Leeds, UK.
n It was suggested that ulcer recurrence should be con-
sidered an outcome. The initial response from the team 
was that ulcer recurrence was not included in this COS 
initiative, as the focus of the COS was the treatment 
of open VLUs. Following an in-depth discussion, the 
group concluded that ulcer recurrence will not be in-
cluded as a domain or outcome. Unfortunately, the 
scope of this project cannot cover all aspects of VLU 
management, especially in light of the fact that the scop-
ing review of open ulceration has revealed that this by 
itself is a significant endeavour.
n An audience member asked whether there will be rep-
resentation from the healthcare industry. Following an 
in-depth discussion after the meeting at EWMA, it was 
decided that healthcare industry representatives will be 
part of the stakeholder group.
n Additional issues that will not be addressed within the 
scope of the project were addressed. The CoreVen pro-
ject aims to develop the COS only and will not be advis-
ing on the conduct and reporting of trials; however, we 
highlight the need for future research on the conduct 
and reporting in VLU trials. The following issues were 
discussed:
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 n The idea that the COS should include recommenda-
tions about duration of follow-up was suggested. This 
idea was discussed based on the criticisms raised in 
the systematic review by Hodgson et al.22, in which a 
median follow-up of 12 weeks was suggested for trials 
evaluating treatments for chronic wounds. A later com-
ment reiterated that recommendation for a minimum 
follow-up time for assessment of both healing and recur-
rence within that period would be useful. Our group, 
however, will not be recommending a minimum follow-
up time; however, we do emphasise that future research 
on the minimum follow-up time is needed.
 n Members of the audience suggested that trials should
report baseline prognostic variables per group. While the 
COS will not cover such recommendations, the COS, 
once established, can be implemented alongside tools, 
such as CONSORT (Consolidated Standards of Report-
ing Trials, 23), which includes recommendations on 
the reporting of baseline variables, to address this issue.
 n A question was posed regarding whether the COS would
provide guidance on the target number of trial par-
ticipants. The team responded by stating the COS will 
recommend outcomes on which estimations of statisti-
cal power would be based but would not recommend 
a target number for trial participants directly as this 
number depends on the individual trial aims.
 n Members of the audience questioned how the steering 
group decided on a 70% level of consensus (as opposed 
to other values). The team responded that this decision 
was based on methods used by other COS initiatives, 
such as OMERACT24, which developed COS in rheu-
matology; Kirkham et al.25, who developed the COS-
STAR (Core Outcome Set-STAndards for Reporting) 
statement; McNair et al.26, who developed COS in colo-
rectal cancer surgery; and Millar et al.21, who developed 
COS in prescribing for older adults in care homes.
 n The core outcome(s) may vary according to trial end-
point and the treatment being evaluated. The team re-
sponded to this point by stating that the aim of the ini-
tiative is to identify core outcomes for all VLU trials and 
that trialists can certainly add other outcomes. The core 
outcome may be a secondary outcome within a study 
and does not necessarily have to be a primary outcome.
 n An audience member also said that researchers involved
in future studies should be able to justify the reasons that 
outcomes from the COS were not reported in the trial.
CONCLUSION
The meeting was successful as the audience raised valu-
able questions and provided helpful comments during 
the meeting to facilitate the development of the COS. In 
conclusion, industry stakeholders will be accessed through 
their identified networks. Researchers will be able to in-
clude additional outcomes in their studies, will be able 
to decide which of the COS are primary and secondary 
in their trials, and will be able to omit some outcomes as 
long as they provide justification. As with all initiatives, 
some issues will not be covered by the scope of the project 
because the CoreVen project aims to develop the COS only 
and will not be advising on the conduct and reporting of 
trials. The team, however, emphasises the need for future 
research on conduct and reporting in VLU trials. This 
includes recommendations on the minimum follow-up 
time, baseline prognostic variables, and number of trial 
participants. A two round online survey that will soon 
be launched will seek to gain consensus on the domains 
listed (see Table). Following this survey which is to gain 
consensus on the domains, an additional online survey 
will be completed in two rounds to gain consensus on the 
specific outcomes that fall within the domains that were 
voted as important in the previous online survey.
WHAT IS NEXT?
The online survey will be launched in September/October 
2017, and the team aims to complete the two rounds of 
data gathering by December 2017. The findings will be 
ready for presentation in early 2018. A second meeting 
will be held in 2018 to discuss the findings and final-
ise the method for the second Delphi study on the core 
outcomes. The full protocol will be published and made 
readily available.
You can contact us:
Email: Sarah Hallas via hc11s4h@leeds.ac.uk
Twitter: @VLUcoreven
Nonstandard abbreviations
CONSORT Consolidated Standards of Reporting Trials
CoreVen Core outcome set for Venous leg ulceration 
COS Core Outcome Set
COS-STAR Core Outcome Set- STAndards for Reporting
CWG Cochrane Wounds Group
EWMA European Wound Management Association
HOME Harmonizing Outcome Measures for Eczema
mOMEnt management of Otitis Media with Effusion in 
children with cleft palate
NHS National Health Service
OMERACT Outcome Measures in Rheumatology 
RCT Randomised Control Trial
VLU Venous Leg Ulceration
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